Navigation Links
Daiichi Sankyo Quietly Grows While Other Pharmaceutical Firms Downsize
Date:10/1/2007

mbination of the calcium channel blocker (CCB) amlodipine and the angiotensin receptor blocker (ARB) olmesartan medoxomil, or BENICAR(R). In the next several months, the company expects to launch a type 2 diabetes indication for its lipid-lowering drug, WelChol(R) (colesevalam hydrochloride). With FDA approval, WelChol will be the first LDL-lowering medication also indicated for improving glycemic control. And within two years, Daiichi Sankyo and its co-promotion partner Eli Lilly and Company hope to bring the anti-platelet agent prasugrel to market for patients with acute coronary syndrome.

Globally, Daiichi Sankyo currently ranks as one of the top twenty pharmaceutical companies, with sales last year exceeding $8 billion. As a company in existence for more than 100 years, Daiichi Sankyo is very well known in Japan-it is the country's second largest drug maker, ranking ahead of Astellas Pharma Inc. and Eisai Inc. whose sales are $7.5 and $4.6 billion, respectively.

"The legacy of Daiichi and Sankyo is more than a century of pharmaceutical experience in bringing important medical discoveries to market," Pieroni said. "We are continuing this tradition of solid R&D innovation and are confident that our company is well positioned as an emerging leader in cardiovascular care to excel in the challenging U.S. pharmaceutical marketplace-and in bringing more life sciences jobs to New Jersey."

Daiichi Sankyo Co., Ltd., (TSE: 4568), the U.S. organization's parent company, is traded on the Tokyo Stock Exchange.

About Daiichi Sankyo, Inc.

Daiichi Sankyo, Inc., (pronounced DIE - EECH -EE SANK- EE - O) headquartered in Parsippany, New Jersey, is the U.S. subsidiary of Daiichi Sankyo Co., Ltd., Japan's second largest pharmaceutical company and a global leader in pharmaceutical innovation since 1899. The company is dedicated to the discovery, development and commercialization of innovative medicines that improve the lives of patients throughout the wor
'/>"/>

SOURCE Daiichi Sankyo, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Heart grows new cells
2. Body Grows Older As Cells Age
3. Emergency Department Strain As Ice Problems Grows
4. Indian Researcher Finds Human Urine Grows Better Fish Food
5. Depression has a worthwhile treatment
6. Reducing The Frequency Of Angina Attacks While Exercising
7. Some See A Hopeless End, While Others See An Endless Hope
8. Doctors Do Not Excise Sufficient Caution While Prescribing High-Risk Drugs
9. Driving While Using A Mobile Phone May Be Dangerous
10. Care for the elderly at home while away during the festive season
11. Children Face Risk While Swimming
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)....4% Shareholders Intend To Vigorously Protect Inve...NCINNATI, Nov. 21 Dr. S...iled an amendment to their Schedule 13D with the U... previously filed a 13D disclosing ownership of 11...perates 77 LasikPlus fixed-site laser vision corre...
(Date:11/21/2008)...NTVALE, N.J., Nov. 21 Ba...unced that its shareholders overwhelmingly approve...acquisition of Barr by Teva Pharmaceuticals Indust...vote demonstrated the overwhelming support of the ...L. Downey, Barr,s Chairman and CEO. "We are please...
(Date:11/21/2008)...LLAS, Nov. 21 In a statewide surve...exas Institute for Surgery at Presbyterian Hospita... 2008 annual listing of " Super Doctors ." , ,...ork with Key Professional Media, Inc. to survey mo...ate of Texas to ask, "If you needed medical care, ...
(Date:11/21/2008)...STON, Nov. 21 Innerscope Research(...m specializing in Emotional Response Measurement,...es who will strengthen the,company,s research and...tiatives. , The three appointments, who del...eoffrey Gill as Chief Financial Officer and Vice P...
Breaking Medicine News(10 mins):Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 2Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 3Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 4Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 5Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 6Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 7Health News:Barr Shareholders Approve Pending Teva Acquisition 2Health News:Barr Shareholders Approve Pending Teva Acquisition 3Health News:Barr Shareholders Approve Pending Teva Acquisition 4Health News:Annual List of 'Super Doctors' Features 33 Texas Institute for Surgery Physicians 2Health News:Innerscope Research Strengthens Management Team With Three Executive Appointments 2
...from Irvene college,California report that protein...secretions may lead to the development of new trea.... The findings, mark the discovery of two naturall... researchers have named prokineticins.How the prot...
...ikelier to develop a serious intestinal disorder i...c erythromycin, say US scientists. A research tea...drug to pyloric stenosis, a condition that affects... the most common cause of abdominal surgery in inf...
...bacterium blamed for the Black Death during middle...pon, has had its entire genome sequenced. The gene...ng themselves and picking up new genes from other ...strains of plague might emerge. More ominously, it...
...mochromatosis, a disorder in which iron accumulate...r risk to blood safety than other donors, accordin... Heart, Lung, and Blood Institute (NHLBI). // Hem... periodic phlebotomies or "blood letting" to remov...
Other Medicine News:Health News:Snake venom a treatment for digestive disease 2Health News:Sequencing of the Plague 2
(Date:11/19/2008)...e/ -- Biotech scientists increasingly are applying...etter understand the effects of novel drug candida...c Engineering & Biotechnology News ( GEN ). T...w compound,s mechanism of action and eventually de...ing to the November 15 issue of GEN . ( http://ww...
(Date:11/19/2008)...e- , , MONTVALE, N.J., Nov. 19 /PRNewswire-...: MEMY ) today announced that it has achieved th...EM 3454, its lead alpha-7 nicotinic receptor agoni...phrenia (CIAS). The Company has randomized 212 pa...lion payment from its partner Roche. Memory Pharm...
(Date:11/18/2008)...n more, make a donation or send a Christmas Seals ...USNewswire/ -- Millions will receive Christmas Sea...n Lung Association. These decorative holiday stamp...ng back to 1907 when the Lung Association led effo...ericans alive today have no vivid memories of how ...
(Date:11/18/2008)...Newswire/ -- Forty-two leading U. S. scientists an...m to consider cutting-edge innovations that may de...from outbreaks of dangerous zoonotic diseases, the...se innovations: , , , , A "Doc ...ects highly contagious and dangerous zoonotic dise...
Breaking Medicine Technology:GEN Reports on the Trend Toward Predictive Toxicogenomics 2Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 2Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 3American Lung Association Celebrates 101st Annual Christmas Seals Campaign 242 Top U.S. Scientists and Specialists Explore Cutting-Edge Innovations to Defend America From Dangerous Zoonotic Diseases 2Brookdale Announces First Quarter 2008 Results 18721 1Brookdale Announces First Quarter 2008 Results 18721 2Brookdale Announces First Quarter 2008 Results 18721 3Brookdale Announces First Quarter 2008 Results 18721 4Brookdale Announces First Quarter 2008 Results 18721 5Brookdale Announces First Quarter 2008 Results 18721 6Brookdale Announces First Quarter 2008 Results 18721 7Brookdale Announces First Quarter 2008 Results 18721 8Brookdale Announces First Quarter 2008 Results 18721 9Brookdale Announces First Quarter 2008 Results 18721 10Brookdale Announces First Quarter 2008 Results 18721 11Brookdale Announces First Quarter 2008 Results 18721 12Brookdale Announces First Quarter 2008 Results 18721 13Brookdale Announces First Quarter 2008 Results 18721 14Brookdale Announces First Quarter 2008 Results 18721 15Brookdale Announces First Quarter 2008 Results 18721 16Brookdale Announces First Quarter 2008 Results 18721 17Brookdale Announces First Quarter 2008 Results 18721 18Brookdale Announces First Quarter 2008 Results 18721 19Brookdale Announces First Quarter 2008 Results 18721 20Brookdale Announces First Quarter 2008 Results 18721 21Brookdale Announces First Quarter 2008 Results 18721 22Mindray Medical International Announces First Quarter 2008 Results 5203 1Mindray Medical International Announces First Quarter 2008 Results 5203 2Mindray Medical International Announces First Quarter 2008 Results 5203 3Mindray Medical International Announces First Quarter 2008 Results 5203 4Mindray Medical International Announces First Quarter 2008 Results 5203 5Mindray Medical International Announces First Quarter 2008 Results 5203 6Mindray Medical International Announces First Quarter 2008 Results 5203 7Mindray Medical International Announces First Quarter 2008 Results 5203 8Mindray Medical International Announces First Quarter 2008 Results 5203 9Mindray Medical International Announces First Quarter 2008 Results 5203 10Mindray Medical International Announces First Quarter 2008 Results 5203 11Mindray Medical International Announces First Quarter 2008 Results 5203 12Mindray Medical International Announces First Quarter 2008 Results 5203 13Mindray Medical International Announces First Quarter 2008 Results 5203 14Mindray Medical International Announces First Quarter 2008 Results 5203 15Mindray Medical International Announces First Quarter 2008 Results 5203 16Mindray Medical International Announces First Quarter 2008 Results 5203 17Mindray Medical International Announces First Quarter 2008 Results 5203 18Amnis and Gene Company Ltd Announce Agreement to Market ImageStream Technology in China 5201 1Amnis and Gene Company Ltd Announce Agreement to Market ImageStream Technology in China 5201 2BD to Present at Investor Healthcare Conferences 5199 1
... of insulin is the C-terminal cleavage product pro...to the mature insulin molecule. Although the C-pep...undergo significant liver or extra-renal metabolis...-life than insulin [1]. In addition, C-peptide ass...
... of circulating testosterone exists as unbound or ..., is bound to SHBG with high affinity [1], while t... albumin-bound and free fractions may be biologica...terone action. Measurement of the free or unbound ...
...edicals AUDICOR is the first, easy-to-use, non-inv...sionals worldwide quickly rule-in cardiac dysfunct...syndrome, and other high-risk cardiac conditions. ...low, AUDICOR products enable clinicians caring for...
...timulating hormone (TSH) is a 32 kDa glycoprotein ...ituitary gland [1]. The structure of human TSH is ...adotropins, consisting of an a-subunit which is si...ique beta-subunit, which confers hormonal specific...
Medicine Products: